SCOTT M. HORVITZ
CHIEF EXECUTIVE OFFICER
Mr. Horvitz is a seasoned entrepreneur and business executive with over 25 years experience managing life sciences and emerging growth companies. His areas of expertise include: fund raising, mergers and acquisitions, business development, contract negotiation, budgeting, SEC reporting, corporate governance, investor relations, facilities management, and human resources. He has helped transition his three previous organizations from venture backed start-ups to publicly traded companies, raising over $250 million in the process.
In June 2007, Mr. Horvitz was the recipient of the New Jersey Technology Council CFO of the Year Award. Previously, Mr. Horvitz was the Chief Financial Officer of Redpoint Bio, where he worked from 2003 through 2012. Prior to that he co-founded 3-Dimensional Pharmaceuticals, Inc., where he worked from its inception in 1993 until its acquisition by Johnson & Johnson in 2003, most recently serving as its Chief Financial Officer and Corporate Secretary and Treasurer. Earlier, Mr. Horvitz was the Executive Director of Finance and Human Resources with Magainin Pharmaceuticals from 2001-2003. Mr. Horvitz served on the Board of Directors of Protez Pharmaceuticals, Inc. and was the Chairman of its Audit Committee from 2004 until its acquisition by Novartis in 2008. Mr. Horvitz holds a Bachelor of Science in Accounting from the University at Albany and is a Certified Public Accountant.
R. KYLE PALMER
CHIEF SCIENCE OFFICER &
CHIEF OPERATING OFFICER
Dr. Palmer is the lead inventor of Opertech's proprietary MOG and TāStation® technology. Previously, Dr. Palmer was Senior Director of Discovery Research with Redpoint Bio, where he worked from 2004 through 2011. Prior to that he was an Associate Research Fellow in the Immunology Department at Schering-Plough Research Institute, where he was the lead pharmacologist for several discovery programs.
Dr. Palmer is a classically trained pharmacologist. He obtained his B.S. from Hobart College, M.S. from Rutgers University in Biopsychology, and Ph.D. in Pharmacology from the University of Michigan. His established areas of expertise are in GPCR and ion channel pharmacology from the molecular to the behavioral levels of scientific inquiry. Dr. Palmer has published work on the pharmacology of taste, behavioral pharmacology, intracellular calcium signaling, and the molecular pharmacology of purinergic receptors, and was a contributor to the discovery of the P2Y12 and P2Y13 receptors. Dr. Palmer currently serves as an officer to the Mid-Atlantic Pharmacology Society and is adjunct faculty at Temple University School of Pharmacy where he lectures on principles of pharmacology.